Kennewick, WA – July 14, 2026 – Vivos Inc. (OTCQB: RDGL) is pleased to announce that it has been working closely with PixelRank, led by Founder and CEO Dave Brinkhus over the last several months to design and develop the Company’s new corporate website.
As Vivos continues to advance both the IsoPet® veterinary oncology platform and RadioGel® human oncology program, the new corporate website will serve as a modern, investor focused hub that better reflects the Company’s vision, technology, and continued growth.
Dave Brinkhus brings more than 15 years of experience in website design, digital strategy, and search engine optimization. Throughout his career, he has built high-performing websites that combine exceptional user experience with strategic digital marketing, helping organizations strengthen their online presence and reach broader audiences. Brinkhus is also the creative force behind several award-winning healthcare and pharmaceutical websites. His work on the Synovetin OA® website earned multiple prestigious industry honors, including a VETTY Silver Award, an AVA Digital Award for SEO/Search Campaign, and a dotCOMM Award for Consumer Website.
Most recently, Dave developed the highly regarded IsoPet® website, creating a platform that effectively communicates the science behind IsoPet while providing veterinarians and pet owners with an intuitive, educational experience. The website has become an important resource supporting IsoPet’s continued commercial growth and expansion.
“Dave Brinkhus and the PixelRank team have delivered exactly what we needed, a modern website that truly reflects our innovation in precision radiotherapy,” said Brad Weeks, President of Vivos Inc. “His award-winning track record in healthcare and his deep understanding of our IsoPet and RadioGel platforms make him the ideal partner as we scale our presence across veterinary and human oncology.”
The new Vivos corporate website offers a modern design, improved navigation, and expanded educational content that better reflects our work in precision radiotherapy. Now live, the site serves as an important milestone in strengthening the Vivos brand and supporting our continued growth across both IsoPet veterinary and RadioGel human oncology initiatives.
About Vivos Inc.
Vivos Inc. is developing advanced Yttrium-90 based brachytherapy devices for the treatment of tumors in both animals (IsoPet®) and humans (RadioGel®). The Company is committed to delivering safer, more effective, and accessible cancer therapies through Precision Radionuclide Therapy™.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of applicable securities laws. Actual results may differ materially from those expressed or implied due to various risks and uncertainties.
Contact:
Mike Korenko, ScD
CEO, Vivos Inc.
mkorenko@radiogel.com
Brad Weeks
President, Vivos Inc.
brad.weeks@vivosinc.com
Follow Vivos Inc. on X (Twitter): @VivosIncUSA
Learn more about RadioGel® and IsoPet® at www.VivosInc.com
